We didn't have too many reservations about the Galaxy S III for Verizon in stock form. Anyone who's been eager to load new firmware, however, has been up in arms over the particularly locked down bootloader that Big Red (but no other US carrier so far) demands. Enter the Galaxy S III Developer Edition. The new, direct-from-Samsung variant will have all the CDMA and LTE a Verizon subscriber could want, but with the option to unlock the bootloader for as much customization as serious Android fans might stand. As you'd anticipate, the catch is simply who takes the hit if something goes wrong: brick the phone and you're likely looking at an expensive phone call to Samsung rather than a trip to the local Verizon store. Regardless, those who like Verizon's network but don't believe its claims about 'dangerous' unlocked phones can get the best of both worlds soon -- as long as they're willing to spend the $600 off-contract once the Developer Edition is ready in the near future. Check after the break for Samsung's official Q&A on the subject.
The Maingear Potenza Super Stock ($1,999 direct) is a compact gaming system that's an inbetweener. It's somewhat larger than competitors that are "console-size", but it's much smaller than a full size tower. Add stellar benchmark numbers, interesting design, and a really nice price to the mix, and what we have is our new Editors' Choice award winner for midrange gaming desktops.
Design and Features
The Potenza Super Stock (SS) redefines the desktop form factor. It measures about 15.75 by 7.5 by 9.25 inches (HWD), which is tall for such a compact desktop. The sides of the system are black painted metal, with a pop-off top panel made of black plastic. The front and back panels are easy to remove without tools. Once open, you can get to the included Nvidia GeForce GTX 680 graphics card, as well as the drive bay for the 1TB SATA hard drive. Those are about the only two internal components you should mess with, as the rest of the internal components will require quite a bit more disassembly. Thankfully, Maingear offers lifetime labor for future upgrades (you'll of course have to buy the upgrade components from Maingear).
With all the panels in place, the Potenza SS looks kind of like a subwoofer enclosure. It's certainly one of the more unique system's we've seen. It's minimal and unique. Longtime PCMag readers will remember that Maingear also brought us the Prysma back in 2006. The Potenza SS will work in a variety of rooms and offices, unlike the Prysma. The Potenza SS is a bit little larger than the Falcon Northwest Tiki ($2,793 direct, 4 stars), but both are small-form-factor (SFF) PCs with high-end 195W Nvidia graphics cards and quad core Intel processors.
The top of the system is a diamond mesh perforated lid, with a cutout for an internal riser. The riser features the system's power and reset buttons, along with audio and two USB 3.0 ports. The one annoying thing about the riser is that it bisects the cavity that houses the ports and power supply. Because of that, you need to snake the display cables and the power cable out of different access holes. Add wired keyboard and mouse, and the wiring makes the system look a little hydra-like. It's not a deal breaker, but it may prompt you to put the system out of sight rather than displaying it proudly on your desk, as you might with the Tiki.
Remove the top plastic lid, and you're actually looking at the system's "back" panel. Maingear did this to ease access when the system is on the floor, as well as to help heat dissipation. The system's airflow is from the base to the top, so the heated air from the graphics card follows natural convection. The system's ports include four USB 2.0 ports, four USB 3.0 ports, jacks for the included Wi-Fi antennas, Ethernet, and two powered eSATA/USB ports. There are two sets of graphics ports (HDMI, DVI, and DisplayPort), one set on the graphics card, one on the motherboard. The ones on the motherboard use the internal graphics on the Intel Core i7-3770k CPU, so make sure you connect your main display to the ones on the graphics card. The system's front panel has a slit cut into it for the slot-loading DVD burner. Above that on the front panel is a lit Maingear logo. The front panel is connected to the motherboard and power supply via a set of thin cables, so be careful when showing off the inside of your Potenza SS.
The hard drive has nothing to show off: it's clear of bloatware and other programs. The folks at Maingear loaded the Windows 7 Home Premium operating system, the drivers for all the included hardware, and Virtu MVP. Virtu MVP helps speed graphics performance and quality by managing which tasks get done by the system's CPU, integrated GPU, and discrete GPU. See performance below for how it turned out. The rest of the system's hard drive is blissfully clear. You'll note in the specs that the system includes a 60GB cache drive. The cache drive is invisible to the user. It works as a sort of hybrid drive, improving system boot time and app launch time. The system comes with a three year parts, and lifetime labor warranty. This is a good thing, since the system's processor is overclocked.
Performance
The Potenza SS has an Intel Core i7-3770k processor overclocked to 4.7GHz. This is a full 1.2 GHZ over the stock clock speed. This resulted in some really good benchmark numbers. The system's time of 51 seconds on our Handbrake video test and 2 minutes 16 seconds on the Photoshop CS5 test were among the best. It was faster than the Falcon Northwest Tiki, which scored 0:56 in Handbrake and 2:29 in CS5. It is also faster than our last midrange gaming PC Editor's Choice, the Cyberpower Zeus Thunder 3000SE ($2,299 direct, 4 stars) (0:55 Handbrake, 2:21 CS5). The Potenza SS also beat the others at the CineBench R11.5 rendering test.
That's all well and good, but how did the Potenza SS do on the game grid? In a word, well. The Potenza SS garnered playable frame rates, even at the highest settings on Crysis (65 frames per second) and Lost Planet 2 (89 fps). While the Falcon Northwest Tiki beat the Potenza SS slightly on the Lost Planet 2 test (95 fps), you'd have to be very meticulous to notice the difference. While the Cyberpower was faster still, that's because the Cyberpower has its two AMD Radeon 7950 graphics cards. Essentially, the Potenza SS and Tiki were some of the fastest systems we've seen with single graphics cards. Both would be welcome in a hardcore gamer's home.
So which to buy? The Cyberpower Zeus Thunder 3000SE has faster frame rates at the highest settings, but it's hundreds of dollars more expensive, much larger, and you'd be hard pressed to note which system is faster during most gameplay. The Cyberpower 3000SE also has a flimsy plastic panel. The Falcon Northwest Tiki feels a bit more solid, no small part due to its bolted-together construction and granite base. However, the combination of the Maingear Potenza Super Stock's performance, feature set, and sub-$2,000 price can't be ignored. The Potenza SS' outpaces both deities on the bang for the buck, which is one of the most important factors in the midrange and value gaming PC categories. The Potenza SS combines innovative design, class leading performance, and a more reasonable price tag. All of that results in an Editors' Choice award for midrange gaming desktops for the Maingear Potenza Super Stock.
BENCHMARK TEST RESULTS
COMPARISON TABLE Compare the Maingear Potenza Super Stock with several other desktops side by side.
More desktop reviews: ??? Maingear Potenza Super Stock ??? V3 Gaming PC Avenger ??? Velocity Micro ProMagix HD180 Max ??? Falcon Northwest Tiki ??? Polywell Poly i1000A-3770T ?? more
The Real Housewives of New York City head across the pond. "I'm U.K., You're U.K." has everyone feeling OK, but what about those who were left behind? We recap all of the fake accents and awkward corporate cheerleading in our THG +/- review.
Sonja, Luann, and Carole head off to London and you'd think after a red eye transatlantic flight everyone would be ready for a nap but not these girls. Plus 10 because they're here to shop and they're not wasting a minute.
Plus 8 to Carole when she calls Luann Pumpkin Head. I couldn't help but laugh at that. Then she brushes it off by saying that she only calls her most gorgeous girlfriends by that moniker. Is Luann really buying that?
Heather's obviously looking to impress the ladies as she puts them up in a Penthouse suite but there's a price to pay. They have to attend Heather's Yummie Tummie corporate dinner.
Minus 12. Those Rah! Rah! company dinners can be so boring but it must be ten times worse if you don't work there. To make things even more awkward Heather makes everybody, including the ladies stand up and say what they love about Yummie Tummie. Ugh.
If things weren't uncomfortable enough, Luann calls Carole out for not standing during her turn. Minus 9. The Countess might write books about etiquette but that was a definite dig at the Princess.
So far, I'm siding with Carole. If Luann continues to use that cheesy fake British accent we really need to make it a drinking game or I may not make it through this trip.
I can't figure out why Sonja's so impressed with Heather's party. Sonja's suppose to be a party planner and I didn't see anything special at this one. She gushed over Heather's great cocktails and stunning decor but the party is at a restaurant. Minus 8. All Heather did was pay the bill.
Plus 10 to the ladies for going out to do high tea. This is London and tea is tradition but Heather and Sonja's hats are hideous and to make it worse, Sonja's was falling apart. It's London. The least she could do was buy a new hat. Minus 5.
The pajama party back at the penthouse was cute but what was Heather thinking with those glasses? Mrs. Potato Head indeed. Minus 7. This may be petty but those things made her nose look huge.
Back home Ramona acts like a six year old as she gapes at Aviva's prosthetic leg. Minus 11. Aviva's more than willing to answer questions about it but I don't think Ramona could have called more attention to it if she tried.
Then Ramona heads off to speak at the Learning Annex and could she have made any more of a fuss. First she complains about the lack of a picture, then she makes them change out the table that holds her water, and when it's finally time to start she has to run to the ladies room.
Minus 9. The entire event was just a bore from start to finish.
So it appears the ladies make their way back from the U.K. next week. Will the princess and the countess have a royal ruckus before it's over? Will Ramona forgive best buddy Sonja for going without her? We'll have to tune in next week to find out.
ScienceDaily (July 9, 2012) ? The challenge of treating patients with genetic disorders in which a single mutated gene is simply too large to be replaced using traditional gene therapy techniques may soon be a thing of the past. A Nationwide Children's Hospital study describes a new gene therapy approach capable of delivering full-length versions of large genes and improving skeletal muscle function. The strategy may hold new hope for treating dysferlinopathies and other muscular dystrophies.
A group of untreatable muscle disorders known as dysferlinopathies are caused by mutations in the dysferlin gene. Patients with these disorders, including limb girdle muscular dystrophy type 2B, are typically diagnosed in their early twenties. Approximately one-third will become wheelchair dependent by their mid-30s.
Gene therapy using adeno-associated virus (AAV) to deliver genes to cells has been pursued as an option for some patients with muscular dystrophy. However, AAV's packaging limitations have served as obstacles in using gene therapy to deliver large genes like dysferlin. Scientists in the past have attempted to work around AAV's packaging limitations by inserting a small version of large genes into the viral vector to induce gene expression. Some have also used more than one viral vector at a time to deliver a large gene. However, micro and mini versions of large genes don't always have the power of full-length gene expression and an increased viral load can lead to negative side effects.
"We have had success in the clinic using AAV gene therapy with limb girdle muscular dystrophy type 2D, which is caused by mutations in the alpha-sarcoglycan gene," said Louise Rodino-Klapac, PhD, principal investigator in the Center for Gene Therapy at The Research Institute of Nationwide Children's Hospital. "However, the dysferlin gene is very large, about six times larger than the alpha-sarcoglycan gene and can't fit into a traditional AAV vector."
A 2008 study identified AAV5, an AAV serotype that could package large transcripts. "This made us wonder whether it could be used for gene replacement requiring inserts as large as the dysferlin gene," said Dr. Rodino-Klapac.
In their 2012 study appearing in PLoS ONE, Dr. Rodino-Klapac's team used AAV5 to package a full-length, intact dysferlin gene and directly deliver it to the diaphragm of dysferlin-deficient mice. They also injected the leg muscles of dysferlin-deficient mice using both intramuscular and vascular approaches to further evaluate whether the gene delivery could improve skeletal muscle function.
They found that both the intravascular and intramuscular delivery approaches led to full-length, intact dysferlin gene expression in the leg and diaphragm muscle cells of the mice. More importantly, they saw that the newly-restored dysferlin repaired membrane deficits previously seen in the dysferlin-deficient mice.
"Our findings demonstrate highly favorable results with full restoration of dysferlin without compromise in function," said Dr. Rodino-Klapac. "With regard to neuromuscular diseases, these studies provide new perspective for conditions caused by mutations of large genes. Duchenne muscular dystrophy is the most common severe childhood muscular dystrophy and would seem to benefit from expression of the larger transcripts than mini- and micro-dystrophins that only partially restore physiologic function in mouse models of the disease."
Dr. Rodino-Klapac and her team are currently defining a path for a dysferlin clinical gene therapy trial. "We have shown that AAV5-dysferlin delivery is a very promising therapeutic approach that could restore functional deficits in dysferlinopathy patients," she says.
Share this story on Facebook, Twitter, and Google:
Other social bookmarking and sharing tools:
Story Source:
The above story is reprinted from materials provided by Nationwide Children's Hospital.
Note: Materials may be edited for content and length. For further information, please contact the source cited above.
Journal Reference:
William E. Grose, K. Reed Clark, Danielle Griffin, Vinod Malik, Kimberly M. Shontz, Chrystal L. Montgomery, Sarah Lewis, Robert H. Brown, Paul M. L. Janssen, Jerry R. Mendell, Louise R. Rodino-Klapac. Homologous Recombination Mediates Functional Recovery of Dysferlin Deficiency following AAV5 Gene Transfer. PLoS ONE, 2012; 7 (6): e39233 DOI: 10.1371/journal.pone.0039233
Note: If no author is given, the source is cited instead.
Disclaimer: This article is not intended to provide medical advice, diagnosis or treatment. Views expressed here do not necessarily reflect those of ScienceDaily or its staff.
Lauren Sciences LLC's research team at Ben-Gurion University awarded Campbell Foundation grant to develop a V-Smart therapeutic for neuro-HIVPublic release date: 10-Jul-2012 [ | E-mail | Share ]
Contact: Susan Rosenbaum srosenbaum@laurensciences.com 212-737-0455 Lauren Sciences LLC
New York, N.Y., July 10, 2012 -- Lauren Sciences LLC, a privately-held biotechnology company furthering development of its new V-Smart nanovesicle platform technology, announced today the award of a grant from The Campbell Foundation to its research team at Ben-Gurion University. The grant from Campbell will support development of the novel V-Smart nanovesicles for systemic delivery of tenofovir across the blood brain barrier (BBB) to the brain for treatment of neuro-HIV. Tenofovir is one of the most frequently used antiretroviral drugs in the multi-drug treatment of HIV infection. However, since tenofovir does not cross the BBB following systemic administration, the treatment is not effective against viral reservoirs in the central nervous system (CNS). The persistence of HIV in the CNS (called, neuro-HIV) is a major contributor to HIV-associated cognitive impairment and is perceived to be a major cause of the inability to completely control systemic HIV despite long-term highly active anti-retroviral treatment (HAART).
"On behalf of our research team at Ben-Gurion University, we thank The Campbell Foundation for this award," said Susan Rosenbaum, Esq., Chairman and Chief Executive Officer of Lauren Sciences. "The Campbell Foundation's award provides an opportunity to develop our innovative V-Smart drug delivery system for neuro-HIV and it recognizes the strong potential of our delivery system to overcome the challenge of developing drugs that cross the blood brain barrier."
"One of our Foundation's major goals is to find a disease-modifying therapy for HIV/AIDS," said Ken Rapkin, Program Officer of The Campbell Foundation. "The challenges associated with the delivery of HIV drugs through the blood brain barrier represent a critical unmet need in the field of AIDS research."
"Optimized V-Smart vesicles formulated with tenofovir has promise as an effective new treatment for patients," said Irwin Hollander, Ph.D., Vice President, Research and Development, Lauren Sciences. "We hope it will be able to stop proliferation of, or even help eradicate, the neuro-HIV that is presumed to cause cognitive impairment and systemic HIV reinfection in patients under long-term treatment. It is anticipated that our successful delivery of tenofovir to the brain will lead to future efficacy studies in neuro-HIV pre-clinical models and, thereafter, clinical studies in patients with HIV."
"Our pre-clinical studies so far demonstrate that our novel V-Smart nano-sized vesicles encapsulate small molecules, peptides, proteins and nucleic acids, transport them across the BBB and release their encapsulated contents in the brain," said Eliahu Heldman, Ph.D., Professor Emeritus at Ben-Gurion University and Chief Scientific Officer of Lauren Sciences LLC. "Our goal is to target the areas in the brain that are affected by HIV and reduce the viral load in those brain regions. The success of this project should provide more effective treatment for AIDS patients and improve their lives."
###
About the V-Smart Platform
V-Smart is a platform technology that can be used for a variety of applications, including delivery of therapeutic drugs. The V-Smart drug delivery system is based on novel nanovesicles that have advantages over other nanovesicles, such as liposomes. Major features of the V-Smart vesicles include: high stability, large encapsulation capacity, ability to carry many kinds of drugs across the BBB following systemic delivery, potential targeting capability and controlled release of encapsulated drugs at specific target sites.
About Lauren Sciences LLC
Lauren Sciences LLC is a privately-held biotechnology company focused on using its V-Smart platform to create a robust pipeline of therapeutics, including central nervous system (CNS)-active drugs that normally do not cross the BBB. The company's lead programs are for the treatment of: Parkinson's disease (funded with the award of a grant from The Michael J. Fox Foundation); neuro-HIV (funded with the award of a grant from The Campbell Foundation) and other CNS disorders, such as Alzheimer's, GBM (brain cancer) and ALS (Lou Gehrig's disease). Lauren Sciences exclusively licensed the V-Smart technology platform and intellectual property estate from B.G. Negev Technologies, the technology transfer company of Ben-Gurion University, Israel, where the company's Chief Scientific Officer, Dr. Eliahu Heldman, is Professor Emeritus and he, with Drs. Sarina Grinberg and Charles Linder, developed the V-Smart technology and lead the Lauren Sciences research team.
About HIV- AIDS
Human immunodeficiency virus infection/Acquired immunodeficiency syndrome (HIV/AIDS) is a disease of the human immune system caused by the human immunodeficiency virus (HIV). There is no known cure or vaccine for HIV/AIDS, however, long term antiretroviral treatment can slow the course of the disease and may lead to a near-normal life expectancy. However, the persistence of HIV in the CNS (called, neuro-HIV) is a major contributor to HIV-caused cognitive impairment and is perceived to be a major cause of the inability to completely control systemic HIV despite long-term HAART. HIV/AIDS is a major health problem in many parts of the world, and is considered a pandemic. As of 2010, approximately 34 million people have HIV globally. Of these, approximately 16.8 million are women and 3.4 million are less than 15 years old. HIV/AIDS resulted in about 1.8 million deaths in 2010, down from 3.1 million in 2001. Since AIDS was first recognized in 1981, it has led to nearly 30 million deaths (as of 2009).
About The Campbell Foundation
The Campbell Foundation was established as a private, independent foundation in 1986 by the late Richard Campbell Zahn. It was Mr. Zahn's wish that his foundation support nonprofit organizations conducting clinical, laboratory-based research into the prevention and treatment of HIV/AIDS, and related conditions and illnesses. The focus of the Campbell Foundation's funding lies in alternative, nontraditional avenues of research that will have direct clinical impact/relevancy to the HIV care/research community within five to seven years. The Board of Directors remains dedicated to pursuing Mr. Zahn's original goals. The Foundation's first year of substantial funding was in 1995. Funders Concerned About AIDS (FCAA) has identified The Campbell Foundation as one of the top 25 private philanthropic institutions supporting seminal research about HIV/AIDS.
About Ben-Gurion University of the Negev
Established in 1969 with the mandate to bring development to the Negev region, BGU is internationally-recognized for its unique pioneering spirit that combines outstanding academics and research with a commitment to the community. With more than 20,000 students, five faculties and a number of internationally-acclaimed research institutes, the University has become a world leader in interdisciplinary research in cutting-edge fields that range from desert studies to nano- and biotechnology, Hebrew literature to international medicine.
About BGN Technologies
BGN Technologies is the technology transfer company of Ben-Gurion University, responsible for the commercialization of know-how and inventions of the University's researchers. Through the development of novel technologies and creative partnering with industry and investors, BGN files worldwide patent applications on behalf of BGU and manages BGU's large patent portfolio. BGN is continually seeking prospective strategic partners, licensees and investors for the commercialization of its inventions and know-how in the diverse fields such as biotech, pharmaceuticals, drug delivery, medical devices, information technology, security, electro-optics, nanotechnologies, chemical processes, agro-technology, environment and alternative energy.
Contact: Susan Rosenbaum, Esq. of Lauren Sciences LLC, 212-737-0455, info@laurensciences.com.
[ | E-mail | Share ]
?
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
Lauren Sciences LLC's research team at Ben-Gurion University awarded Campbell Foundation grant to develop a V-Smart therapeutic for neuro-HIVPublic release date: 10-Jul-2012 [ | E-mail | Share ]
Contact: Susan Rosenbaum srosenbaum@laurensciences.com 212-737-0455 Lauren Sciences LLC
New York, N.Y., July 10, 2012 -- Lauren Sciences LLC, a privately-held biotechnology company furthering development of its new V-Smart nanovesicle platform technology, announced today the award of a grant from The Campbell Foundation to its research team at Ben-Gurion University. The grant from Campbell will support development of the novel V-Smart nanovesicles for systemic delivery of tenofovir across the blood brain barrier (BBB) to the brain for treatment of neuro-HIV. Tenofovir is one of the most frequently used antiretroviral drugs in the multi-drug treatment of HIV infection. However, since tenofovir does not cross the BBB following systemic administration, the treatment is not effective against viral reservoirs in the central nervous system (CNS). The persistence of HIV in the CNS (called, neuro-HIV) is a major contributor to HIV-associated cognitive impairment and is perceived to be a major cause of the inability to completely control systemic HIV despite long-term highly active anti-retroviral treatment (HAART).
"On behalf of our research team at Ben-Gurion University, we thank The Campbell Foundation for this award," said Susan Rosenbaum, Esq., Chairman and Chief Executive Officer of Lauren Sciences. "The Campbell Foundation's award provides an opportunity to develop our innovative V-Smart drug delivery system for neuro-HIV and it recognizes the strong potential of our delivery system to overcome the challenge of developing drugs that cross the blood brain barrier."
"One of our Foundation's major goals is to find a disease-modifying therapy for HIV/AIDS," said Ken Rapkin, Program Officer of The Campbell Foundation. "The challenges associated with the delivery of HIV drugs through the blood brain barrier represent a critical unmet need in the field of AIDS research."
"Optimized V-Smart vesicles formulated with tenofovir has promise as an effective new treatment for patients," said Irwin Hollander, Ph.D., Vice President, Research and Development, Lauren Sciences. "We hope it will be able to stop proliferation of, or even help eradicate, the neuro-HIV that is presumed to cause cognitive impairment and systemic HIV reinfection in patients under long-term treatment. It is anticipated that our successful delivery of tenofovir to the brain will lead to future efficacy studies in neuro-HIV pre-clinical models and, thereafter, clinical studies in patients with HIV."
"Our pre-clinical studies so far demonstrate that our novel V-Smart nano-sized vesicles encapsulate small molecules, peptides, proteins and nucleic acids, transport them across the BBB and release their encapsulated contents in the brain," said Eliahu Heldman, Ph.D., Professor Emeritus at Ben-Gurion University and Chief Scientific Officer of Lauren Sciences LLC. "Our goal is to target the areas in the brain that are affected by HIV and reduce the viral load in those brain regions. The success of this project should provide more effective treatment for AIDS patients and improve their lives."
###
About the V-Smart Platform
V-Smart is a platform technology that can be used for a variety of applications, including delivery of therapeutic drugs. The V-Smart drug delivery system is based on novel nanovesicles that have advantages over other nanovesicles, such as liposomes. Major features of the V-Smart vesicles include: high stability, large encapsulation capacity, ability to carry many kinds of drugs across the BBB following systemic delivery, potential targeting capability and controlled release of encapsulated drugs at specific target sites.
About Lauren Sciences LLC
Lauren Sciences LLC is a privately-held biotechnology company focused on using its V-Smart platform to create a robust pipeline of therapeutics, including central nervous system (CNS)-active drugs that normally do not cross the BBB. The company's lead programs are for the treatment of: Parkinson's disease (funded with the award of a grant from The Michael J. Fox Foundation); neuro-HIV (funded with the award of a grant from The Campbell Foundation) and other CNS disorders, such as Alzheimer's, GBM (brain cancer) and ALS (Lou Gehrig's disease). Lauren Sciences exclusively licensed the V-Smart technology platform and intellectual property estate from B.G. Negev Technologies, the technology transfer company of Ben-Gurion University, Israel, where the company's Chief Scientific Officer, Dr. Eliahu Heldman, is Professor Emeritus and he, with Drs. Sarina Grinberg and Charles Linder, developed the V-Smart technology and lead the Lauren Sciences research team.
About HIV- AIDS
Human immunodeficiency virus infection/Acquired immunodeficiency syndrome (HIV/AIDS) is a disease of the human immune system caused by the human immunodeficiency virus (HIV). There is no known cure or vaccine for HIV/AIDS, however, long term antiretroviral treatment can slow the course of the disease and may lead to a near-normal life expectancy. However, the persistence of HIV in the CNS (called, neuro-HIV) is a major contributor to HIV-caused cognitive impairment and is perceived to be a major cause of the inability to completely control systemic HIV despite long-term HAART. HIV/AIDS is a major health problem in many parts of the world, and is considered a pandemic. As of 2010, approximately 34 million people have HIV globally. Of these, approximately 16.8 million are women and 3.4 million are less than 15 years old. HIV/AIDS resulted in about 1.8 million deaths in 2010, down from 3.1 million in 2001. Since AIDS was first recognized in 1981, it has led to nearly 30 million deaths (as of 2009).
About The Campbell Foundation
The Campbell Foundation was established as a private, independent foundation in 1986 by the late Richard Campbell Zahn. It was Mr. Zahn's wish that his foundation support nonprofit organizations conducting clinical, laboratory-based research into the prevention and treatment of HIV/AIDS, and related conditions and illnesses. The focus of the Campbell Foundation's funding lies in alternative, nontraditional avenues of research that will have direct clinical impact/relevancy to the HIV care/research community within five to seven years. The Board of Directors remains dedicated to pursuing Mr. Zahn's original goals. The Foundation's first year of substantial funding was in 1995. Funders Concerned About AIDS (FCAA) has identified The Campbell Foundation as one of the top 25 private philanthropic institutions supporting seminal research about HIV/AIDS.
About Ben-Gurion University of the Negev
Established in 1969 with the mandate to bring development to the Negev region, BGU is internationally-recognized for its unique pioneering spirit that combines outstanding academics and research with a commitment to the community. With more than 20,000 students, five faculties and a number of internationally-acclaimed research institutes, the University has become a world leader in interdisciplinary research in cutting-edge fields that range from desert studies to nano- and biotechnology, Hebrew literature to international medicine.
About BGN Technologies
BGN Technologies is the technology transfer company of Ben-Gurion University, responsible for the commercialization of know-how and inventions of the University's researchers. Through the development of novel technologies and creative partnering with industry and investors, BGN files worldwide patent applications on behalf of BGU and manages BGU's large patent portfolio. BGN is continually seeking prospective strategic partners, licensees and investors for the commercialization of its inventions and know-how in the diverse fields such as biotech, pharmaceuticals, drug delivery, medical devices, information technology, security, electro-optics, nanotechnologies, chemical processes, agro-technology, environment and alternative energy.
Contact: Susan Rosenbaum, Esq. of Lauren Sciences LLC, 212-737-0455, info@laurensciences.com.
[ | E-mail | Share ]
?
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
[ [ [['Connery is an experienced stuntman', 2]], 'http://yhoo.it/KeQd0p', '[Slideshow: See photos taken on the way down]', ' ', '630', ' ', ' ', ], [ [['Connery is an experienced stuntman', 7]], ' http://yhoo.it/KpUoHO', '[Slideshow: Death-defying daredevils]', ' ', '630', ' ', ' ', ], [ [['know that we have confidence in', 3]], 'http://yhoo.it/LqYjAX ', '[Related: The Secret Service guide to Cartagena]', ' ', '630', ' ', ' ', ], [ [['We picked up this other dog and', 5]], 'http://yhoo.it/JUSxvi', '[Related: 8 common dog fears, how to calm them]', ' ', '630', ' ', ' ', ], [ [['accused of running a fake hepatitis B', 5]], 'http://bit.ly/JnoJYN', '[Related: Did WH share raid details with filmmakers?]', ' ', '630', ' ', ' ', ], [ [['accused of running a fake hepatitis B', 3]], 'http://bit.ly/KoKiqJ', '[Factbox: AQAP, al-Qaeda in Yemen]', ' ', '630', ' ', ' ', ], [ [['have my contacts on or glasses', 3]], 'http://abcn.ws/KTE5AZ', '[Related: Should the murder charge be dropped?]', ' ', '630', ' ', ' ', ], [ [['have made this nation great as Sarah Palin', 5]], 'http://yhoo.it/JD7nlD', '[Related: Bristol Palin reality show debuts June 19]', ' ', '630', ' ', ' ', ], [ [['have made this nation great as Sarah Palin', 1]], 'http://bit.ly/JRPFRO', '[Related: McCain adviser who vetted Palin weighs in on VP race]', ' ', '630', ' ', ' ', ], [ [['A JetBlue flight from New York to Las Vegas', 3]], 'http://yhoo.it/GV9zpj', '[Related: View photos of the JetBlue plane in Amarillo]', ' ', '630', ' ', ' ', ], [ [['the 28-year-old neighborhood watchman who shot and killed', 15]], 'http://news.yahoo.com/photos/white-house-stays-out-of-teen-s-killing-slideshow/', 'Click image to see more photos', 'http://l.yimg.com/cv/ip/ap/default/120411/martinzimmermen.jpg', '630', ' ', 'AP', ], [ [['He was in shock and still strapped to his seat', 6]], 'http://news.yahoo.com/photos/navy-jet-crashes-in-virginia-slideshow/', 'Click image to see more photos', 'http://l.yimg.com/cv/ip/ap/default/120406/jet_ap.jpg', '630', ' ', 'AP', ], [ [['xxxxxxxxxxxx', 11]], 'http://news.yahoo.com/photos/russian-grannies-win-bid-to-sing-at-eurovision-1331223625-slideshow/', 'Click image to see more photos', 'http://l.yimg.com/a/p/us/news/editorial/1/56/156d92f2760dcd3e75bcd649a8b85fcf.jpeg', '500', ' ', 'AP', ] ]
[ [ [['did not go as far his colleague', 8]], '29438204', '0' ], [ [[' the 28-year-old neighborhood watchman who shot and killed', 4]], '28924649', '0' ], [ [['because I know God protects me', 14], ['Brian Snow was at a nearby credit union', 5]], '28811216', '0' ], [ [['The state news agency RIA-Novosti quoted Rosaviatsiya', 6]], '28805461', '0' ], [ [['measure all but certain to fail in the face of bipartisan', 4]], '28771014', '0' ], [ [['matter what you do in this case', 5]], '28759848', '0' ], [ [['presume laws are constitutional', 7]], '28747556', '0' ], [ [['has destroyed 15 to 25 houses', 7]], '28744868', '0' ], [ [['short answer is yes', 7]], '28746030', '0' ], [ [['opportunity to tell the real story', 7]], '28731764', '0' ], [ [['entirely respectable way to put off the searing constitutional controversy', 7]], '28723797', '0' ], [ [['point of my campaign is that big ideas matter', 9]], '28712293', '0' ], [ [['As the standoff dragged into a second day', 7]], '28687424', '0' ], [ [['French police stepped up the search', 17]], '28667224', '0' ], [ [['Seeking to elevate his candidacy back to a general', 8]], '28660934', '0' ], [ [['The tragic story of Trayvon Martin', 4]], '28647343', '0' ], [ [['Karzai will get a chance soon to express', 8]], '28630306', '0' ], [ [['powerful storms stretching', 8]], '28493546', '0' ], [ [['basic norm that death is private', 6]], '28413590', '0' ], [ [['songwriter also saw a surge in sales for her debut album', 6]], '28413590', '1', 'Watch music videos from Whitney Houston ', 'on Yahoo! Music', 'http://music.yahoo.com' ], [ [['keyword', 99999999999999999999999]], 'videoID', '1', 'overwrite-pre-description', 'overwrite-link-string', 'overwrite-link-url' ] ]
Samsung Developers (not yet active) | Email this | Comments 
The Potenza SS has an Intel Core i7-3770k processor overclocked to 4.7GHz. This is a full 1.2 GHZ over the stock clock speed. This resulted in some really good benchmark numbers. The system's time of 51 seconds on our Handbrake video test and 2 minutes 16 seconds on the Photoshop CS5 test were among the best. It was faster than the Falcon Northwest Tiki, which scored 0:56 in Handbrake and 2:29 in CS5. It is also faster than our last midrange gaming PC Editor's Choice, the Cyberpower Zeus Thunder 3000SE ($2,299 direct, 4 stars) (0:55 Handbrake, 2:21 CS5). The Potenza SS also beat the others at the CineBench R11.5 rendering test.
![[ Back to EurekAlert! ]](https://lh3.googleusercontent.com/blogger_img_proxy/AEn0k_tFvfdu6loYqGJvXNgd68cMNa5GCbEmMQgEoeznaCnmAwwj4lAmajZFEpIe7e_hux7Xk4w-_9MQk17pqQPcmqwh8Vp_R8kHU_rPqCgsUpk=s0-d){kind=small}
Public release date: 10-Jul-2012
Share ]